## PATENT COOPERATION TREATY

TCAGAG J. ARNOLD  AMSTER, ROTHSTEIN & EBENSTEIN LLP  90 PARK AVENUE  NEW YORK, NY 10016  Applicant's or agent's file reference  50425715  Applicant's or agent's file reference  50425715  International application No.  International filing date (day/month/year)  29 March 2005 (29.03.2005)  PCT/US05/10521  International Patent Classification (IPC) or both mational classification and IPC  PPC: Acid K.8400( 2006 O.1); COTH 21/04( 2006.01); Acid K.39/395 (2006.01)  USPC: 424/130.1:514/44/53674.5  Applicant  NORTH SHORE- LONG ISLAND RESEARCH INSTITUTE  1. This opinion contains indications relating to the following items:  Box No. II Priority  Box No. IV Lack of unity of invention  Box No. IV Cartain documents cited  Box No. VI Certain documents cited  Box No. VII Certain documents cited  Box No. VII Certain decements the supplication supplicability; citations and explanations supporting such statement  2. FURTHER ACTION  If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examinaig Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has sufficed the International Bureau under Rule 66.16/6/6) that written opinions of this International Security of the prior of the Authority other than this one to be the IPEA and the chosen IPEA has sufficed the International Bureau under Rule 66.16/6/6) that written opinions, see Form PCT/ISA/220 or before the exquisition of 122 months from the priority date, whichever expires later.  For further options, see Form PCT/ISA/220.  Name and mailing address of the ISA/US  Mail Step RCT. Am: ISA/US  Commissioner for Patents  Later and	From the INTERNATIONAL SEARCHING AUTHORITY				
Applicant's or agent's file reference  Applicant's or agent's file reference  Soca25/215  International application No.  International filing date (day/month/year)  29 March 2005 (29.03.2005)  International application No.  PCTVISOS/10521  International Patent Classification (IPO or both national classification and IPC  IDC: A61K 48/00 (2006.01);C07H 21/04 (2006.01);A61K 39/395 (2006.01)  USPC: 424/130.1514/44;536724.5  Applicant  NORTH SHORE- LONG ISLAND RESEARCH INSTITUTE  1. This opinion contains indications relating to the following items:  Box No. II Priority  Box No. II Priority  Box No. IV Lack of unity of invention  Box No. IV Lack and unity of invention  Box No. VI Certain defects in the international application  Box No. VI Certain defects in the international application  Box No. VII Certain defects in the international application  2. FURTHER ACTION  If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority of where the applicant chooses an Authority of the that this one to be the IPEA and the chosen IPEA has notified the International Burdent (to the IPEA and the chosen IPEA has notified the International Burdent (to the IPEA a written opinions of this International Searching Authority will not be so considered.  If this opinion is, as provided above, considered to be a written opinion of a months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.  For further options, see Form PCT/ISA/220.  Name and mailing address of the ISA/ US Months and preliminary 2007 (17.01.2007)  Alexandria, Virginia 22313-1450  Alexandria, Virginia 22313-1450  Facsimile No. (371) 273-271600	To: CRAIG J. ARNOLD AMSTER, ROTHSTEIN & EBENSTEIN LLP 90 PARK AVENUE	-	,,,	ITTEN OPINION OF THE	PITY
Applicant's or agent's file reference  So425/215  International application No.  International filting date (day/month/year)  Profity date (day/month/year)  29 March 2005 (29.03.2005)  29 March 2005 (29.03.2005)  29 March 2005 (29.03.2005)  29 March 2004 (29.03.2004)  International application (IPC) or both national classification and IPC  IPC: A61K 48/00 (2006.01);C07H 21/04 (2006.01);A61K 39/395 (2006.01)  USPC: 424/130.1;314/44;536/24.5  Applicant  NORTH SHORE- LONG ISLAND RESEARCH INSTITUTE  1. This opinion contains indications relating to the following items:    Box No. I   Basis of the opinion			INTERNATIO		111
Applicant's or agent's file reference   FOR FURTHER ACTION   See paragraph 2 below   See paragraph 2 below   See paragraph 2 below   See paragraph 2 pelow   Priority date (day/month/pear)   29 March 2005 (29.03.2005)   Priority date (day/month/pear)   29 March 2004 (29.03.2004)   International Planta Classification (PC) or both national classification and IPC   IPC: A61K 48/00(2006.01);C07H 21/04(2006.01);A61K 39/395(2006.01)   USPC: 424/13.0.1.514/44;536/24.5				(PCT Rule 43bis.1)	
See paragraph 2 below   See paragraph 2 below   See paragraph 2 below   Priority date (day/month/year)   Priority   Pri				28 FEB 2007	
Sod25/215	Applicant's or agent's file reference		FOR FURTHER	ACTION	
PCT/USOS/10521   29 March 2005 (29.03.2005)   29 March 2004 (29.03.2004)					
International Patent Classification (IPC) or both national classification and IPC  IPC: A61K 48/00 (2006.01):C07H 21/04 (2006.01):A61K 39/395 (2006.01)  USPC: 42/41/30.1:514/44;536/24.5  Applicant  NORTH SHORE- LONG ISLAND RESEARCH INSTITUTE  1. This opinion contains indications relating to the following items:    Box No. I   Basis of the opinion	International application No. Intern	national filing date	(day/month/year)	Priority date (day/month/year)	
IPC: USPC: 424/130.1:514/44;536/24.5     Applicant     NORTH SHORE- LONG ISLAND RESEARCH INSTITUTE				29 March 2004 (29.03.2004)	
USPC: 42/4130.1;514/44;536/24.5					
Applicant NORTH SHORE- LONG ISLAND RESEARCH INSTITUTE  1. This opinion contains indications relating to the following items:    Box No. I Basis of the opinion		2006.01);A61K 39/	395( 2006.01)	•	
1. This opinion contains indications relating to the following items:    Box No. I   Basis of the opinion					
Box No. I Basis of the opinion  Box No. II Priority  Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability  Box No. IV Lack of unity of invention  Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement  Box No. VI Certain documents cited  Box No. VII Certain defects in the international application  Box No. VIII Certain observations on the international application  2. FURTHER ACTION  If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.  If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.  For further options, see Form PCT/ISA/220.  Name and mailing address of the ISA/ US  Mail Stop PCT, Atm. ISA/US  Commissioner for Patents  P.O. Box 1450  Authorized officer  Amy H. Bowman  Telephone No. (571)272-1600  Telephone No. (571)272-1600	NORTH SHORE- LONG ISLAND RESEARCH	INSTITUTE			····
Box No. II Basis of the opinion  Box No. II Priority  Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability  Box No. IV Lack of unity of invention  Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement  Box No. VI Certain documents cited  Box No. VII Certain defects in the international application  Box No. VIII Certain observations on the international application  2. FURTHER ACTION  If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.  If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.  For further options, see Form PCT/ISA/220.  Name and mailing address of the ISA/US  Mail Stop PCT, Atm. ISA/US  Commissioner for Patents  P.O. Box 1450  Authorized officer  Amy H. Bowman  Telephone No. (571) 273-3201				·	<u> </u>
Box No. II Priority  Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability  Box No. IV Lack of unity of invention  Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement  Box No. VI Certain documents cited  Box No. VII Certain defects in the international application  Certain observations on the international application  2. FURTHER ACTION  If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("PEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.  If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.  For further details, see notes to Form PCT/ISA/220.  Name and mailing address of the ISA/ US Mail Stop PCT, Atm. ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201  Date of completion of this opinion Authorized officer Amy H. Bowman Telephone No. (571)272-1600  Telephone No. (571)272-1600	This opinion contains indications relating to	the following item	ns: -		
Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability  Box No. IV Lack of unity of invention  Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement  Box No. VI Certain documents cited  Box No. VII Certain defects in the international application  Box No. VII Certain observations on the international application  2. FURTHER ACTION  If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.  If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCTI/SA/220 or before the expiration of 22 months from the priority date, whichever expires later.  For further details, see notes to Form PCTI/ISA/220.  Name and mailing address of the ISA/ US  Mail Stop PCT, Atm. ISA/US  Commissioner for Patents  F.O. Box 1450  Alexandria, Virginia 22313-1450  Facsimile No. (571) 273-3201  Telephone No. (571)272-1600  Telephone No. (571)272-1600	Box No. I Basis of the opinio	n		•	
Box No. IV Lack of unity of invention  Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement  Box No. VI Certain documents cited  Box No. VII Certain defects in the international application  Box No. VIII Certain observations on the international application  2. FURTHER ACTION  If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.  If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.  For further details, see notes to Form PCT/ISA/220.  Name and mailing address of the ISA/US  Mail Stop PCT, Atm. ISA/US  Commissioner for Patents  P.O. Box 1450  Alexandria, Virginia 22313-1450  Facsimile No. (571) 273-3201  Telephone No. (571)272-1600					
Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement  Box No. VI Certain documents cited  Box No. VII Certain defects in the international application  Box No. VIII Certain observations on the international application  If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.  If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.  For further options, see Form PCT/ISA/220.  Name and mailing address of the ISA/ US  Mail Stop PCT, Attr. ISA/US  Commissioner for Patents  P.O. Box 1450  Alexandria, Virginia 22313-1450  Facsimile No. (571) 273-3201  Date of completion of this opinion  Authorized officer  Amy H. Bowman  Telephone No. (571)272-1600	, <u> </u>	t of opinion with re	gard to novelty, inver	ntive step and industrial applicability	
applicability; citations and explanations supporting such statement  Box No. VI Certain documents cited  Box No. VII Certain defects in the international application  Box No. VIII Certain observations on the international application  2. FURTHER ACTION  If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.  If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.  For further options, see Form PCT/ISA/220.  Name and mailing address of the ISA/US  Mail Stop PCT, Atm. ISA/US  Commissioner for Patents  P.O. Box 1450  Alexandria, Virginia 22313-1450  Facsimile No. (571) 273-3201  Date of completion of this opinion  Telephone No. (571)272-1600  Telephone No. (571)272-1600	Box No. IV Lack of unity of in	vention			
Box No. VII Certain defects in the international application  Box No. VIII Certain observations on the international application  2. FURTHER ACTION  If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.  If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.  For further options, see Form PCT/ISA/220.  Name and mailing address of the ISA/US  Mail Stop PCT, Attn: ISA/US  Commissioner for Patents  P.O. Box 1450  Alexandria, Virginia 22313-1450  Facsimile No. (571) 273-3201  Date of completion of this opinion  Telephone No. (571)272-1600  Telephone No. (571)272-1600	Box No. V Reasoned statemen applicability; citati	nt under Rule 43 <i>bis</i> ions and explanation	.1(a)(i) with regard to ns supporting such st	o novelty, inventive step or industrial atement	
Box No. VIII Certain observations on the international application  2. FURTHER ACTION  If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.  If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.  For further options, see Form PCT/ISA/220.  Name and mailing address of the ISA/US  Commissioner for Patents  P.O. Box 1450  Alexandria, Virginia 22313-1450  Facsimile No. (571) 273-3201  Telephone No. (571)272-1600	Box No. VI Certain documents	cited			
2. FURTHER ACTION  If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.  If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.  For further options, see Form PCT/ISA/220.  Name and mailing address of the ISA/US  Mail Stop PCT, Atm: ISA/US  Commissioner for Patents  P.O. Box 1450  Alexandria, Virginia 22313-1450  Facsimile No. (571) 273-3201  Telephone No. (571)272-1600	Box No. VII Certain defects in	the international ap	plication	· · · · · · · · · · · · · · · · · · ·	
If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.  If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.  For further options, see Form PCT/ISA/220.  Name and mailing address of the ISA/US  Commissioner for Patents  P.O. Box 1450  Alexandria, Virginia 22313-1450  Facsimile No. (571) 273-3201  Telephone No. (571) 272-1600  Telephone No. (571) 272-1600	Box No. VIII Certain observatio	ns on the internation	nal application		
International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.  If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.  For further options, see Form PCT/ISA/220.  Name and mailing address of the ISA/ US  Mail Stop PCT, Attn: ISA/US  Commissioner for Patents  P.O. Box 1450  Alexandria, Virginia 22313-1450  Facsimile No. (571) 273-3201  International Bureau under Rule 66.1bis(b)  that written opinions of the International Bureau under Rule 66.1bis(b)  that written opinions of this International Bureau under Rule 66.1bis(b)  that written opinions of this International Bureau under Rule 66.1bis(b)  that written opinions of the International Bureau under Rule 66.1bis(b)  that written opinions of the International Bureau under Rule 66.1bis(b)  that written opinions of the International Bureau under Rule 66.1bis(b)  If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA, the applicant is invited to submit to the IPEA, the applicant is invited to submit to the IPEA, the applicant is invited to submit to the IPEA, the applicant is invited to submit to the IPEA, the applicant is invited to submit to the IPEA, the applicant is invited to submit to the IPEA, the applicant is invited to submit to the IPEA, the applicant is invited to submit to the IPEA, the applicant is invited to submit to the IPEA, the applicant is invited to submit to the IPEA, the applicant is invited to sub					
PEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.  For further options, see Form PCT/ISA/220.  3. For further details, see notes to Form PCT/ISA/220.  Name and mailing address of the ISA/ US  Mail Stop PCT, Attn: ISA/US  Commissioner for Patents  P.O. Box 1450  Alexandria, Virginia 22313-1450  Facsimile No. (571) 273-3201  Page of completion of this opinion and the priority date, whichever expires later.  Authorized officer  Amy H. Bowman  Telephone No. (571)272-1600	International Preliminary Examining Authority other than this one to be the IPE	hority ("IPEA") each and the chosen	xcept that this does IPEA has notified th	not apply where the applicant choose International Bureau under Rule 66	oses an
3. For further details, see notes to Form PCT/ISA/220.  Name and mailing address of the ISA/ US  Mail Stop PCT, Attn: ISA/US  Commissioner for Patents  P.O. Box 1450  Alexandria, Virginia 22313-1450  Facsimile No. (571) 273-3201  Date of completion of this opinion  Authorized officer  Amy H. Bowman  Telephone No. (571)272-1600	IPEA a written reply together, where appro	priate, with amend	lments, before the ex	piration of 3 months from the date of	t to the mailing
Name and mailing address of the ISA/ US  Mail Stop PCT, Attn: ISA/US  Commissioner for Patents P.O. Box 1450  Alexandria, Virginia 22313-1450  Facsimile No. (571) 273-3201  Date of completion of this opinion 17 January 2007 (17.01.2007)  Tolephone No. (571)272-1600  Telephone No. (571)272-1600	For further options, see Form PCT/ISA/220	L-			
Mail Stop PCT, Atm: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201  Amy H. Bowman  Telephone No. (571)272-1600	3. For further details, see notes to Form PCT/I	SA/220.			
Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201  Amy H. Bowman  Telephone No. (571)272-1600  Telephone No. (571)272-1600	Name and mailing address of the ISA/ US	Date of comple	etion of this opinion	Authorized officer	<del></del>
Alexandria, Virginia 22313-1450  Facsimile No. (571) 273-3201  Telephone No. (571)272-1600	Mail Stop PCT, Attn: ISA/US Commissioner for Patents	17 January 200	7 (17.01.2007)	Amy H. Bowman Jawy	
Facsimile No. (571) 273-3201	Alexandria, Virginia 22313-1450			Telephone No. (571)272-1600	Los
				<u> </u>	XVI

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/US05/10521

Box No	. I Basis of this opinion
1. With n	egard to the language, this opinion has been established on the basis of:
$\boxtimes$	the international application in the language in which it was filed
	a translation of the international application into, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
2. With r invent	egard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed ion, this opinion has been established on the basis of:
a.	type of material
	a sequence listing
	table(s) related to the sequence listing
ь.	format of material
	on paper
	in electronic form
c.	time of filing/furnishing
	contained in the international application as filed.
	filed together with the international application in electronic form.
	furnished subsequently to this Authority for the purposes of search.
3.	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Addit	onal comments:
•	
t I	
]	
٠.	
	•

Form PCT/ISA/237(Box No. I) (April 2005)

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.	<del></del>	·
PCT/US05/10521	•	

Box No. IV Lack of unity of invention	
In response to the invitation (Form PCT/ISA/206) to pay additional fees  paid additional fees  paid additional fees under protest and, where applicable, the pro-	atest fee
paid additional fees under protest but the applicable protest fee  not paid additional fees	was not paid
2. This Authority found that the requirement of unity of invention is not copay additional fees.	
3. This Authority considers that the requirement of unity of invention in accorda	nce with Rule 13.1, 13.2 and 13.3 is
complied with	
not complied with for the following reasons:  See the lack of unity section of the International Search Report(Form PCT/ISA	A/210)
dec are tack of anny content of the monatonial obtained topology of the	,
	•
. )	
·	
·	· ·
	•
4. Consequently, this opinion has been established in respect of the following parts	s of the international application
all parts.	- 5
the parts relating to claims Nos. <u>1-3,5,9 and 10</u>	·

Form PCT/ISA/237 (Box No. IV) (April 2005)

## WRÏTTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

Form PCT/ISA/237 (Box No. V) (April 2005)

International application No. PCT/US05/10521

Statement Statement	planations supporting such statement	· · · · · · · · · · · · · · · · · · ·
Novelty (N)	Claims NONE	YE
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Claims 1-3, 5, 9 and 10	NO
Inventive step (IS)	Claims NONE	YES
	Claims 1-3, 5, 9 and 10	NO
Industrial applicability (IA)	Claims 1-3, 5, 9 and 10	YES
	Claims NONE	
libodies are associated with reduction in (	birodiating dorum triti -alpha torolo: Applicant hac not pre	
ore specifically an anti-MIF antibody for the stant invention.	r diabetes and therefore the treatment of a mammal with the treatment of a pathological condition associated with M the treatment of a pathological condition associated with M the tout in PCT Article 33(4), and thus have industrial application.	an anti-MIF agent, IIF anticlpates the
uld define what mammals are at a risk for ore specifically an anti-MIF antibody for the tant invention.	r diabetes and therefore the treatment of a mammal with the treatment of a pathological condition associated with M the treatment of a pathological condition associated with M the tout in PCT Article 33(4), and thus have industrial application.	an anti-MIF agent, IIF anticipates the
uld define what mammals are at a risk for the specifically an anti-MIF antibody for the tant invention.	r diabetes and therefore the treatment of a mammal with the treatment of a pathological condition associated with M the treatment of a pathological condition associated with M the tout in PCT Article 33(4), and thus have industrial application.	an anti-MIF agent, IIF anticipates the
uld define what mammals are at a risk for the specifically an anti-MIF antibody for the tant invention.	r diabetes and therefore the treatment of a mammal with the treatment of a pathological condition associated with M the treatment of a pathological condition associated with M the tout in PCT Article 33(4), and thus have industrial application.	an anti-MIF agent, IIF anticipates the
ould define what mammals are at a risk for ore specifically an anti-MIF antibody for the stant invention.	r diabetes and therefore the treatment of a mammal with the treatment of a pathological condition associated with M the treatment of a pathological condition associated with M the tout in PCT Article 33(4), and thus have industrial application.	an anti-MIF agent, IIF anticlpates the
uld define what mammals are at a risk for the specifically an anti-MIF antibody for the tant invention.	r diabetes and therefore the treatment of a mammal with the treatment of a pathological condition associated with M the treatment of a pathological condition associated with M the tout in PCT Article 33(4), and thus have industrial application.	an anti-MIF agent, IIF anticipates the
uld define what mammals are at a risk for the specifically an anti-MIF antibody for the tant invention.	r diabetes and therefore the treatment of a mammal with the treatment of a pathological condition associated with M the treatment of a pathological condition associated with M the tout in PCT Article 33(4), and thus have industrial application.	an anti-MIF agent, IIF anticipates the
uld define what mammals are at a risk for the specifically an anti-MIF antibody for the tant invention.	r diabetes and therefore the treatment of a mammal with the treatment of a pathological condition associated with M the treatment of a pathological condition associated with M the tout in PCT Article 33(4), and thus have industrial application.	an anti-MIF agent, IIF anticipates the
ould define what mammals are at a risk for ore specifically an anti-MIF antibody for the stant invention.	r diabetes and therefore the treatment of a mammal with the treatment of a pathological condition associated with M the treatment of a pathological condition associated with M the tout in PCT Article 33(4), and thus have industrial application.	an anti-MIF agent, IIF anticipates the
ould define what mammals are at a risk for ore specifically an anti-MIF antibody for the stant invention.  aims 1-3, 5, 9, and 10 meet the criteria se	r diabetes and therefore the treatment of a mammal with the treatment of a pathological condition associated with M the treatment of a pathological condition associated with M the tout in PCT Article 33(4), and thus have industrial application.	an anti-MIF agent, IIF anticlpates the
ould define what mammals are at a risk for ore specifically an anti-MIF antibody for the stant invention.  aims 1-3, 5, 9, and 10 meet the criteria se	r diabetes and therefore the treatment of a mammal with the treatment of a pathological condition associated with M the treatment of a pathological condition associated with M the tout in PCT Article 33(4), and thus have industrial application.	an anti-MIF agent, IIF anticipates the
ould define what mammals are at a risk for ore specifically an anti-MIF antibody for the stant invention.  aims 1-3, 5, 9, and 10 meet the criteria se	r diabetes and therefore the treatment of a mammal with the treatment of a pathological condition associated with M the treatment of a pathological condition associated with M the tout in PCT Article 33(4), and thus have industrial application.	an anti-MIF agent, IIF anticlpates the